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Urologists usually treat overactive bladder (OAB) with oral 
medications. However, when there is no response to medica-
tion, alternative methods of treatment, including botulinum 
toxin A injection and sacral neuromodulation, are utilized. 
Nevertheless, botulinum toxin A requires repeated injections, 
causes adverse effects such as acute urinary retention, and re-
duces patient’s compliance to treatment due to the discomfort 
of multiple rounds of injection-based therapy. Sacral neuro-
modulation can result in problems like lead migration, pain, 
and infection.
 Whether given orally or via injection, therapeutic drugs may 
induce adverse effects in other organs aside from the target or-
gans due to their systemic distribution. Long-term drug treat-
ment may be difficult in some cases due to adverse effects; 
however, this problem could be overcome by drug delivery di-
rectly to the target organ in order to minimize systemic effects.  
 Treatment with antimuscarinic agents can induce problems 
among OAB patients by causing dry mouth and constipation. 
These adverse effects reduce patient’s compliance, thereby de-
creasing treatment efficacy. In an attempt to overcome this 
problem, researchers have attempted direct instillation of oxy-
butynin or lidocaine into the bladder, with results showing im-
provement in lower urinary tract symptoms (LUTS) [1]. How-
ever, this procedure requires repeated drug instillation using a 
urethral catheter, and the effects are neither continuous nor 
lasting. 
 Based on the idea that devices that release drugs directly into 
the bladder may have potential to become a new treatment mo-
dality, several devices have been designed. One of the first de-
vices created was the UROS bladder pump [2]. This device is a 
straight tube that is inserted into the bladder via cystoscopy and 
releases oxybutynin directly inside the bladder. Another device, 
the LiRIS, was designed by Lee and Cima [3]. The LiRIS device 
is a silicone tube, which is inserted into the bladder via cystos-
copy and allows lidocaine to elute into the bladder. Research is 
being done aiming to create other effective tubular shaped treat-
ment devices that facilitate drug elution into the bladder for ex-
tended periods. 
 Implanting a device into a patient’s body may be a satisfacto-
ry therapeutic modality for OAB, as it should theoretically have 
high efficacy while minimizing adverse effects [4]. Nonetheless, 
there are several issues associated with implantation of a device 
into the body. First, this requires an invasive procedure to insert 
the device. In some cases, general anesthesia or local anesthesia 
may be necessary, which increases anesthetic risks and patient 
discomfort. Second, device insertion into the bladder may cre-
ate problems such as hemorrhage, infection, and increased ex-
pense, and third, the device may worsen LUTS by irritating the 
bladder. Even though symptomatic improvement has been 
shown after device insertion, the duration of efficacious treat-
ment after insertion remains to be determined. In addition, this 
procedure needs periodic device replacements, which gives rise 
to challenges including patient discomfort, higher cost, and ad-
verse effects. Moreover, if the device is placed inside the bladder 
permanently, device encrustation may occur. 
 Implantable devices in the bladder should fulfill several pre-
requisites. There should be minimal discomfort during and af-
ter implantation, and the device should not be expelled during 
urination. The design of the device should maximize therapeu-
tic value by facilitating release of optimal levels of drug, mini-
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mizing adverse effects, reducing the need for repeated device 
insertion and removal, and preventing infection or device en-
crustation. Currently, a device that meets all of these require-
ments has not yet been invented. 
 At present, there is few effective and convenient treatments 
for intractable OAB. It is hoped that collaboration between urol-
ogists and biomedical engineers may create a treatment modali-
ty that maximizes effects while minimizing discomfort. 
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